Posts Tagged ‘PSA’

Multiple Myeloma Survivor Treated by Dr Stanislaw Burzynski

Sunday, January 28th, 2018

My guest, David Emerson says “I was diagnosed with multiple myeloma in February of 1994 at the age of 34. I underwent induction therapy of 5 rounds of VAD, 2 rounds of cytoxan and an autologus bone marrow transplant, all in 1995. I relapsed in 10/96, underwent local palliative local radiation, relapsed again in 9/97 and was told “nothing more can be done for you. ”

”I underwent a “quack” cancer therapy called antineoplaston therapy (ANP) from 11/97-4/99. I reached complete remission where I have remained since.  I have remained in complete remission from my multiple myeloma by living an evidence-based, non-toxic, anti-myeloma lifestyle through nutrition, supplementation, bone health, mind-body, detox. and more. I consider my anti-myeloma regimen to be a metronomic, low-dose, maintenance myeloma therapy. But non-toxic.

I am also a multiple myeloma cancer coach. Click my website to join a free webinar about the Multiple Myeloma Cancer Coaching Program that I researched and developed based on my 22 plus years living with multiple myeloma I would not be alive today if it weren’t for the Internet and The Burzynski Research Institute. I created the Galen Foundation as a 501(c)(3) non-profit and launched with the mission to empower cancer survivors and caregivers through information, education and support.

Enjoy the interview below:


Improved Diagnostic Test for Prostate Cancer.

Wednesday, May 20th, 2015

Improved Diagnostic Test for Prostate Cancer

A new study reported in Science digest concluded that a new urine-based test for prostate cancer improves detection when compared to prostate serum antigen (PSA) levels. This test also improved detection of the more aggressive forms of prostate cancer. The new test is called Mi-Prostate Score (MiPS)  and combines the PSA with two prostate cancer markers-T2:ERG and PCA3 both of which can be detected through a urine test.  The test was indicated because about 50% of all men having biopsies will not have cancer.

In the study 1,977 men having the prostate biopsy because of elevated PSA levels were evaluated. Researchers used urine samples to conduct MiPS testing and compared with various combinations of PSA, PBA3, T2:ERG and other PSA-based calculations. The testing evaluated how well individual biomarkers and combinations predicted the likelihood of cancer and high-risk cancer.  Although there is no one cut-off score  for a positive result, they found that using one MiPS cutoff score to decide whether or not to biopsy patients would reduce the number of biopsies by one-third, while delaying the diagnosis of only about 1 percent of high-risk prostate cancers. More research is ongoing.

Can Prostate Cancer be Confirmed Without a Biopsy”

Wednesday, August 13th, 2014


The Prostate Health Index (phi), a simple, non-invasive blood test that is three times more specific than the PSA to detect prostate cancer is now available according to a report in Science Digest. This may reduce the need for men who test positive for prostate cancer using  a PSA test  to need  a biopsy. Researchers said “The PSA test is based on the fact that men with higher levels of PSA protein are more likely to have prostate cancer.” “However. the problem is that higher levels of PSA can also be caused by a benign enlargement or inflammation of the prostate, leading to many false positives for cancer and ultimately unnecessary invasive biopsies and an increased potential for patient harm.”  Because the blood test is three times more specific in detecting prostate cancer than the PSA it may reduce the need for a biopsy and potential patient harm. Studies showed a reduction of 31% in unnecessary biopsies due to false positives on PSA’s using the phi test.

The phi test uses three different PSA markers as part of a sophisticated algorithm to increase the reliability of determining a patient with a positive PSA has prostate cancer. “The Prostate Health Index is a significant addition to our comprehensive menu of advanced clinical evidence based blood tests that aid in early cancer detection.” said the co-founder of the laboratory offering the test.

PSA Test for Breast Cancer Detection??

Friday, July 22nd, 2011


Researchers reported in the journal Analytical Chemistry that the PSA may be used as a new test for detecting breast cancer. The prostate-specific antigen measured in the PSA test is a potential biomarker of breast cancer in women but levels in healthy women is so small that most tests will not measure them.
Thus, the researchers built a tiny fiber-optic biosensor using gold nanoparticles and PSA antibodies to detect and report PSA levels via a florescent signal. The sensitivity and specificity of the test for breast cancer are comparable to those found when using it as a biomarker for prastate cancer. It is also believed that the sensitivity and specificity compare favorably to the current screening methods for breast cancer (clinical exam and mammogram).

Increased Accuracy with New Prostate Cancer Screening Test

Wednesday, April 13th, 2011


A study to be published in the May issue of the Journal of Urology concluded that a new PSA test for screening prostate cancer is more accurate and specific and substantially reduces false positives compared to the currently used PSA tests based upon a large multi-center clinical trial. The new test could lead to fewer false positives, unnecessary biopsies, and the over treatment of slow developing cancer that would never have caused suffering and death. The test will “focus on the detection of more life-threatening prostate cancers and reduce unnecessary biopsies in men 50 years of age and older.”
The study followed 900 patients from 10 sites and found the new PSA test (Pro-PSA) was especially useful for patients with a normal prostate examination whose PSA was 2 to 10 that is considered a gray zone for prostate cancer because most men with higher levels have prostate cancer and those with lower levels do not.
The Pro-PSA teast has been approved for use in Europe and is being reviewed by the FDA.More information is available at:

Prostate Cancer is not Predicted by a Change in the PSA Level

Friday, March 4th, 2011


A study reported in the February 24 issue of the Journal of the National Cancer Institute concluded that blood tests indicating the PSA (prostate-specific antigen) levels are rising rapidly over time are not useful in detecting aggressive prostate cancer and may lead to unnecessary biopsies.

In the study the researchers used data from over 5,500 men in their 60’s and 70’s taking part in a drug trial for prostate cancer prevention.
Those selected for this study did not receive a drug in the initial study and all agreed to have a biopsy at the end of the trial. Although researchers did find a statistical association between PSA velocity (change in PSA levels over time) and the chances of a follow-up biopsy being positive for cancer, when they factored in other things that influence the risk such as family history of the disease, older age, being black, and PSA levels and digital rectal exam there was virtually no association between PSA velosity and biopsy outcome and concluded “PSA velosity measurement is not useful.” They also said ” This study should change practice. We have previously published papers determining that PSA naturally varies from month to month and have urged men whose PSA suddenly rises to wait six months and repeat the test before agreeing to a needle biopsy. This new study in a large population of men provides even stronger evidence that using changes in PSA as a basis for recommendation for biopsy leads to many more unnecessary biopsies and does not help to find the more aggressive cancers that we want to find and treat.”

For information-This issue was previously discussed by Tanya Harter Pierce on the Holistic Health Show and more information on the PSA can be found in her book Outsmart Your Cancer: Alternative Non-Toxic Treatments That Work. 2009 edition.

More information at:

PSA Blood Test May Accurately Predict Prostate Cancer Deaths

Friday, September 24th, 2010


A new study published in the British Medical Journal online concluded that a blood test at age 60 could accurately predict the risk of death from prostate cancer within the next 25 years.
In the study researchers analyzed the blood samples of 1,167 men born in 1921. Blood samples were collected in 1981 and 1982 and all subjects were followed until age 85 or death. Following a review of biomarkers the researchers found that the PSA was a highly accurate predictor of long term risk of prostate cancer death.

One hundred twenty six men were diagnosed with prostate cancer and in that group 90% of the deaths occurred in those who were in the top 25% of the PSA levels at age 60. The researchers concluded that those with a PSA above 2ng/ml at age 60 should be considered at high risk of aggressive prostate cancer and should continued to be followed. Those with a PSA under 1ng/ml at age 60 had a 0.2 percent chance of prostate cancer death and should be considered at low risk of prostate cancer death and even when prostate cancer is present it is not likely to cause symptoms or shorten their life up to age 85.

Tanya Harter Pierce to be Interviewed by Dr Carl O Helvie on the Holistic Health Show

Sunday, August 23rd, 2009


My guest on the Holistic Health show on Saturday, August 29 is Tanya Harter Pierce who has a masters degree in clinical psychology and is currently on leave from her counseling practice as a Marriage, Family, and Child Counselor. Tanya never thought she would write a book about cancer but when a family member was diagnosed with cancer that was considered “incurable” by conventional medicine she suddenly began searching alternative options. Over the years she had cured other chronic conditions with alternative holistic treatments so she had an open mind about these interventions. From her studies she was stunned to find so many successful approaches to treating cancer non-toxically that often had better success rates than current conventional treatments. Because this information was not easily available or understandable she wrote Outsmart Your Cancer: Alternative Non-Toxic Treatments that Work . The second edition of this book has just been published and Tanya will focus on two areas of the book in the interview: Protocel, and the PSA and Hormone Blocking Drugs as they relate to Prostate Cancer.

Current Research shows Green Tea may Slow Advancement to Prostate Cancer

Friday, June 26th, 2009

Research reported in Cancer Prevention Research online June 19, 2009 stated that consuming a green tea catechin supplement resulted in a reduction in prostate specific antigen (PSA) and other markers that indicate disease progression in men with prostate cancer. A team of researchers at Louisiana State University�s Feist-Weiller Cancer Center reported that 4 capsules of a green tea supplement daily (equivalent to 12 cups of green tea) was given to 26 prostate cancer patients for 12 to 73 days prior to scheduled surgery. Blood samples were collected prior to and the day of surgery showed a reduction in the PSA markers of as much as a 25% decrease. In addition, insulin like-1 that has been associated with a poor prostate cancer prognosis and a liver function tests declined following treatment with green tea suggesting low toxicity from the treatment.
Further research is ongoing with green tea and breast cancer patients and tentative conclusions are that many cancers are preventable and these studies support the idea that plant compounds found in a healthy diet can play a role in the development and progression of cancer.